Neuphoria Therapeutics Stock Forecast
NASDAQ: NEUPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.36+0.01 (+0.30%)
Market open · Delayed 15 min · as of Oct 9, 2:25 PM ET
NEUP analyst consensus
Consensus (1 analysts)
none
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 1 Wall Street analyst covering Neuphoria Therapeutics (2026-10-09), 0 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NEUP.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 1 | 100% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.